Montefiori D C, Lefkowitz L B, Keller R E, Holmberg V, Sandstrom E, Phair J P
Department of Pathology, Vanderbilt University Medical School, Nashville, Tennessee 37232.
AIDS. 1991 May;5(5):513-7. doi: 10.1097/00002030-199105000-00006.
Neutralizing and complement-mediated infection-enhancing antibodies to HIV-1 were measured in sera or plasma from 54 HIV-1-positive individuals at various stages of disease, and from an additional 36 HIV-1-positive individuals for whom no clinical data were available. Antibodies were measured in microtiter infection assays utilizing MT-2 cells and the IIIB strain of HIV-1. The frequency of detection of both types of antibodies was identical, being 77 out of 90 cases (86%). Neutralizing and infection-enhancing antibodies were not always found together, and in four cases both were undetectable. No correlation was found between titers of either type of antibody and stage of disease. Furthermore, titers of infection-enhancing antibodies at early stages of disease did not predict rate of disease progression.
在54名处于不同疾病阶段的HIV-1阳性个体以及另外36名无临床数据的HIV-1阳性个体的血清或血浆中，检测了针对HIV-1的中和抗体和补体介导的感染增强抗体。利用MT-2细胞和HIV-1的IIIB毒株，通过微量滴定感染试验检测抗体。两种类型抗体的检测频率相同，90例中有77例（86%）。中和抗体和感染增强抗体并非总是同时出现，有4例两种抗体均未检测到。未发现任何一种抗体的滴度与疾病阶段之间存在相关性。此外，疾病早期感染增强抗体的滴度并不能预测疾病进展速度。
